Pacira Pharmaceuticals Interest Expense:
0.343M for Dec. 31, 2012Pacira Pharmaceuticals Historical Interest Expense Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.343M |
| Sept. 30, 2012 | 0.456M |
| June 30, 2012 | 0.494M |
| March 31, 2012 | 0.514M |
| Dec. 31, 2011 | 0.712M |
| Sept. 30, 2011 | 0.91M |
| June 30, 2011 | 0.676M |
| March 31, 2011 | 2.481M |
| Dec. 31, 2010 | 1.382M |
| Sept. 30, 2010 | 1.077M |
| June 30, 2010 | 0.887M |
| March 31, 2010 | 0.784M |
| Dec. 31, 2009 | 2.613M |
| Sept. 30, 2009 | 0.471M |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
A higher interest expense means that the company is paying more to its debtors. In general, a company's capital structure with a heavier debt focus will have higher interest expenses. Liquidity ratios such as EBIT/Interest Expense can help investors see if increasing Interest Expenses are problematic.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
PCRX Interest Expense Benchmarks
| Companies | |
|---|---|
| BioScrip | 6.362M |
| Neurocrine Biosciences | 0.00 |
| Lannett Company | 0.072M |
PCRX Interest Expense Rankings
| Overall |
61st percentile 3114 of 8007 |
| Sector |
39th percentile 412 of 685 in Healthcare |
| Industry |
40th percentile 32 of 54 in Drug Manufacturers - Major |
PCRX Interest Expense Range, Past 5 Years
| Minimum | 0.3430M | Dec 2012 |
| Maximum | 2.613M | Dec 2009 |
| Average | 0.9857M |
PCRX News
Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 8
Seeking Alpha May 8
